表紙:標的がん治療薬の世界市場
市場調査レポート
商品コード
925944

標的がん治療薬の世界市場

Targeted Oncology Therapeutics

出版日: | 発行: Greystone Research Associates | ページ情報: 英文 | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.81円
標的がん治療薬の世界市場
出版日: 2020年02月16日
発行: Greystone Research Associates
ページ情報: 英文
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、標的がん治療薬市場を調査し、承認薬の市場シェア、標的がん治療薬の世界の供給状況、市場リーダー、がん適応症の治療範囲と製品の機会、および主要な市場セグメントにおける競合状況などについて分析しています。

目次

  • 組換え治療薬のエコシステム
  • 標的がん治療薬市場のリーダー
  • 腫瘍学の生物製剤:競争上の考慮事項
  • 標的がん治療薬として承認された薬剤
  • FDA承認薬
  • EMA承認薬
  • トラスツズマブのバイオシミラー
  • EMA承認のバイオシミラー
  • バイオシミラー製品の発売に対する訴訟の影響
  • 標的がん治療薬:市場セグメント
  • 乳がん
  • 大腸がん
  • 血液がん
  • 肺がん
  • 黒色腫
  • 転移性胃がん
  • 神経がん
  • 腎細胞がん
  • 尿路上皮がん
  • サプライヤーの競争力評価
目次
Product Code: TJK353F

A number of factors are changing the way market participants view the cancer therapeutics market. These factors are evident in the disease targets and drug classes that comprise a significant number of recent trials. After decades of disappointment and missed financial objectives, the genetic underpinnings of disease are converging with improved computer-assisted pharmacological decision making. Market sector participants now find themselves pursuing realistic therapeutic strategies that have the potential to fulfill product strategies in both scientific and human terms.

What You Will Learn:

  • What is the market share of approved therapeutics?
  • What is the global supply picture for targeted therapeutics?
  • Who are the market leaders, by Indication? by Product?
  • What is the therapeutic coverage across all oncology indications? What are the product opportunities?
  • What are the established products in this space? by target, indication, API class, revenue?
  • What is the competitive picture for the major Oncology market segments?
  • Drug treatment resources
  • Competitive therapy map
  • Clinical trial activity
  • Who are the leading competitors in the field of next-generation therapeutics?

Table of Contents(SUMMARY)

  • The Recombinant Drug Ecosystem
  • Targeted Oncology Therapeutics Market Leaders
  • Oncology Biologics - Competitive Considerations
  • Approved Drugs for targeted Oncology Therapeutics
  • FDA-approved Drugs
  • EMA-approved Drugs
  • Biosimilars of Trastuzumab
  • EMA Approved Biosimilars
  • The Impact of Litigation on Biosimilar Product Launches
  • Targeted Oncology Therapeutics - Market Segments
  • Breast Cancers
  • Colorectal Cancers
  • Hematology Cancers
  • Lung Cancers
  • Melanomas
  • Metastatic Gastric Cancers
  • Neurological Cancers
  • Renal Cell Carcinomas
  • Urothelial Cancers
  • Supplier Competitive Assessments

Charts, Tables, Graphs, and Visualizations

  • Approved mAbs - Market Share by Product Activity
  • Global Supplier Activity Map
  • Targeted Oncology Market Leaders (Indications, Products)
  • FDA/EMA Approved Product Market Coverage by Supplier

Established Products (Baseline & Commercialization Summaries)

  • Adcetris (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Avastin (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Blincyto (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Cyramza (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Adcetris (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Darzalex (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Empliciti (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Erbitux (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Gazyva (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Herceptin (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Imfinzi (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Keytruda (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Opdivo (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Perjeta (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Rituxan (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Tecentriq (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Vectibix (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Yervoy (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Zevalin (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)

Emerging Products

  • Arzerra (Detailed Profiles, Indications, Supply Chain)
  • Bavencio (Detailed Profiles, Indications, Supply Chain)
  • Besponsa (Detailed Profiles, Indications, Supply Chain)
  • Enhertu (Detailed Profiles, Indications, Supply Chain)
  • Herzuma (Detailed Profiles, Indications, Supply Chain)
  • Kadcyla (Detailed Profiles, Indications, Supply Chain)
  • Kanjinti (Detailed Profiles, Indications, Supply Chain)
  • Lartruvo (Detailed Profiles, Indications, Supply Chain)
  • Libtayo (Detailed Profiles, Indications, Supply Chain)
  • Lumoxiti (Detailed Profiles, Indications, Supply Chain)
  • Mvasi (Detailed Profiles, Indications, Supply Chain)
  • Ogivri (Detailed Profiles, Indications, Supply Chain)
  • Omtruzant (Detailed Profiles, Indications, Supply Chain)
  • Padcev (Detailed Profiles, Indications, Supply Chain)
  • Polivy (Detailed Profiles, Indications, Supply Chain)
  • Portrazza (Detailed Profiles, Indications, Supply Chain)
  • Poteligeo (Detailed Profiles, Indications, Supply Chain)
  • Ruxience (Detailed Profiles, Indications, Supply Chain)
  • Truxima (Detailed Profiles, Indications, Supply Chain)
  • Unituxin (Detailed Profiles, Indications, Supply Chain)
  • Zirabev (Detailed Profiles, Indications, Supply Chain)
  • EMA Approved Biosimilars, All
  • EMA, Approved Biosimilars for Oncology Incications
  • Biosimilars, Patent Litigation Impact Map

Targeted Oncology Market Assessments

  • Breast Cancer - Drug Treatment Resource Map, by Type
  • Breast Cancer - Competitive Therapy Map, Total Revenue by Year
  • Breast Cancer - Clinical Trial Activity, Sponsor/Collaborator
  • Breast Cancer - Clinical Trial Activity, First-listed Interventional Therapeutic
  • Breast Cancer - Clinical Trial Activity by Trial Phase
  • Colorectal Cancer - Drug Treatment Resource Map, by Type
  • Colorectal Cancer - Competitive Therapy Map, Total Revenue by Year
  • Colorectal Cancer - Clinical Trial Activity, Sponsor/Collaborator
  • Colorectal Cancer - Clinical Trial Activity, First-listed Interventional Therapeutic
  • Colorectal Cancer - Clinical Trial Activity by Trial Phase
  • Hematology Cancers - Drug Treatment Resource Map, by Type
  • Hematology Cancers - Competitive Therapy Map, Total Revenue by Year
  • Hematology Cancers - Clinical Trial Activity, Sponsor/Collaborator
  • Hematology Cancers - Clinical Trial Activity, First-listed Interventional Therapeutic
  • Hematology Cancers- Clinical Trial Activity by Trial Phase
  • Lung Cancers - Drug Treatment Resource Map, by Type
  • Lung Cancers - Competitive Therapy Map, Total Revenue by Year
  • Lung Cancers - Clinical Trial Activity, Sponsor/Collaborator
  • Lung Cancers - Clinical Trial Activity, First-listed Interventional Therapeutic
  • Lung Cancers- Clinical Trial Activity by Trial Phase
  • Melanomas - Drug Treatment Resource Map, by Type
  • Melanomas - Competitive Therapy Map, Total Revenue by Year
  • Melanomas - Clinical Trial Activity, Sponsor/Collaborator
  • Melanomas - Clinical Trial Activity, First-listed Interventional Therapeutic
  • Melanomas- Clinical Trial Activity by Trial Phase
  • Metastatic Gastric Cancers - Drug Treatment Resource Map, by Type
  • Metastatic Gastric Cancers - Competitive Therapy Map, Total Revenue by Year
  • Metastatic Gastric Cancers - Clinical Trial Activity, Sponsor/Collaborator
  • Metastatic Gastric Cancers - Clinical Trial Activity, First-listed Interventional Therapeutic
  • Metastatic Gastric Cancers- Clinical Trial Activity by Trial Phase
  • Neurological Cancers - Drug Treatment Resource Map, by Type
  • Neurological Cancers - Competitive Therapy Map, Total Revenue by Year
  • Neurological Cancers - Clinical Trial Activity, Sponsor/Collaborator
  • Neurological Cancers - Clinical Trial Activity, First-listed Interventional Therapeutic
  • Neurological Cancers- Clinical Trial Activity by Trial Phase
  • Renal Cell Carcinomas - Drug Treatment Resource Map, by Type
  • Renal Cell Carcinomas - Competitive Therapy Map, Total Revenue by Year
  • Renal Cell Carcinomas - Clinical Trial Activity, Sponsor/Collaborator
  • Renal Cell Carcinomas - Clinical Trial Activity, First-listed Interventional Therapeutic
  • Renal Cell Carcinomas- Clinical Trial Activity by Trial Phase
  • Urothelial Cancers - Drug Treatment Resource Map, by Type
  • Urothelial Cancers - Competitive Therapy Map, Total Revenue by Year

Supplier Competitive Assessments